WHO Sounds Concern Over Critical Scarcity of Obesity Medications
Less than 10% of individuals that would benefit from obesity jabs like Wegovy can access them, caution the World Health Organization as it publishes its inaugural guidance on the drugs.
With more than one billion individuals worldwide now obese, it is urging broader and more equitable availability to GLP-1 medication.
Based on estimates, more than two billion are projected to be obese by 2030 if no action is taken.
"The latest guidelines recognises that obesity is a lifelong illness that can be addressed with comprehensive and lifelong care," remarked the agency's head Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and logistical bottlenecks are major hurdles to widespread access to the jabs that can assist patients in reducing significant weight, says the organization.
Skinny Jab Shortage
Despite the current most favorable outlook, the manufacturing of GLP-1 therapies would only suffice for around 100 million people – under 10% of those who need them, as stated by the WHO.
The advice encourages governments and firms to increase availability, via approaches such as patent sharing.
The intellectual property rights on a key compound – the main ingredient of a leading brand – is scheduled to end in several nations in 2026.
The Way Weight-Loss Injections Work
GLP-1 drugs imitate a biological compound to slow digestion, curb appetite and boost satiety so individuals eat less.
Individuals commonly start to lose weight within a few weeks of starting on the once-weekly jabs.
Evidence indicates people may see weight return after a year of discontinuing the treatment, as their normal food cravings come back.
Being above a healthy weight increases your risk for developing medical conditions, including diabetes, heart disease, brain attack, and some cancers.
Excess weight affects people in all nations and was associated with millions of deaths worldwide in 2024, per the health agency.